PE20110793A1 - Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona - Google Patents
Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesteronaInfo
- Publication number
- PE20110793A1 PE20110793A1 PE2011000628A PE2011000628A PE20110793A1 PE 20110793 A1 PE20110793 A1 PE 20110793A1 PE 2011000628 A PE2011000628 A PE 2011000628A PE 2011000628 A PE2011000628 A PE 2011000628A PE 20110793 A1 PE20110793 A1 PE 20110793A1
- Authority
- PE
- Peru
- Prior art keywords
- cyanophenyl
- pyrazole
- progesterone receptor
- cyclopropyl
- isopropyl
- Prior art date
Links
- DHQDELVGXSNGQL-UHFFFAOYSA-N NC(C1=CC(C(C=C2)=CC=C2C#N)=NN1)=O Chemical class NC(C1=CC(C(C=C2)=CC=C2C#N)=NN1)=O DHQDELVGXSNGQL-UHFFFAOYSA-N 0.000 title 1
- 229940123788 Progesterone receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 ISOPROPYL Chemical group 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- PEWNLSMMUUAIKA-ZDUSSCGKSA-N 5-(4-cyanophenyl)-4-cyclopropyl-n-[(2s)-2-hydroxypropyl]-2-propan-2-ylpyrazole-3-carboxamide Chemical compound C=1C=C(C#N)C=CC=1C1=NN(C(C)C)C(C(=O)NC[C@@H](O)C)=C1C1CC1 PEWNLSMMUUAIKA-ZDUSSCGKSA-N 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical group [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 206010016629 fibroma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002379 progesterone receptor modulator Substances 0.000 abstract 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 abstract 1
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9790208P | 2008-09-18 | 2008-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110793A1 true PE20110793A1 (es) | 2011-10-31 |
Family
ID=41269630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000628A PE20110793A1 (es) | 2008-09-18 | 2009-09-16 | Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8232269B2 (enExample) |
| EP (1) | EP2350017A1 (enExample) |
| JP (1) | JP2012502975A (enExample) |
| KR (1) | KR20110044304A (enExample) |
| CN (1) | CN102159548A (enExample) |
| AP (1) | AP2011005611A0 (enExample) |
| AU (1) | AU2009294290B2 (enExample) |
| BR (1) | BRPI0918935A2 (enExample) |
| CA (1) | CA2735931A1 (enExample) |
| CL (1) | CL2011000570A1 (enExample) |
| CO (1) | CO6351734A2 (enExample) |
| DO (1) | DOP2011000083A (enExample) |
| EA (1) | EA201100368A1 (enExample) |
| EC (1) | ECSP11010901A (enExample) |
| IL (1) | IL211479A0 (enExample) |
| MA (1) | MA32642B1 (enExample) |
| MX (1) | MX2011002899A (enExample) |
| PE (1) | PE20110793A1 (enExample) |
| WO (1) | WO2010032200A1 (enExample) |
| ZA (1) | ZA201102690B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2541295T3 (es) * | 2011-04-21 | 2015-07-17 | Orion Corporation | Carboxamidas que modulan el receptor de andrógenos |
| JP6046134B2 (ja) * | 2011-07-21 | 2016-12-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 小分子によるヒト癌におけるｇｌｉタンパク質の標的化 |
| WO2013123240A1 (en) | 2012-02-17 | 2013-08-22 | Eisai R&D Management Co., Ltd | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
| EP2700635A1 (en) | 2012-08-20 | 2014-02-26 | Basf Se | 5-Trifluoromethylpyrazole amides having herbicidal activity |
| JP2016505049A (ja) | 2013-01-23 | 2016-02-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 小分子によるヒト癌におけるｇｌｉタンパク質のターゲティング方法 |
| SI3290421T1 (sl) | 2013-02-22 | 2019-03-29 | Pfizer Inc. | Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK) |
| WO2014143617A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Women's Health, Inc. | Deuterium-enriched tanaproget and processes for its preparation |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3，3-二氟环丁烷甲酸的方法 |
| WO2020198583A1 (en) | 2019-03-27 | 2020-10-01 | Insilico Medicine Ip Limited | Bicyclic jak inhibitors and uses thereof |
| EP4053124A1 (en) * | 2019-10-28 | 2022-09-07 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof |
| WO2023217203A2 (zh) * | 2022-05-12 | 2023-11-16 | 西北农林科技大学 | 二苯基吡唑类化合物的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1874732A1 (en) * | 2005-04-20 | 2008-01-09 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| US7947707B2 (en) * | 2005-10-07 | 2011-05-24 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
-
2009
- 2009-09-16 KR KR1020117006161A patent/KR20110044304A/ko not_active Ceased
- 2009-09-16 WO PCT/IB2009/054038 patent/WO2010032200A1/en not_active Ceased
- 2009-09-16 CA CA2735931A patent/CA2735931A1/en not_active Abandoned
- 2009-09-16 EP EP09787204A patent/EP2350017A1/en not_active Withdrawn
- 2009-09-16 AU AU2009294290A patent/AU2009294290B2/en not_active Expired - Fee Related
- 2009-09-16 JP JP2011527444A patent/JP2012502975A/ja not_active Withdrawn
- 2009-09-16 AP AP2011005611A patent/AP2011005611A0/xx unknown
- 2009-09-16 PE PE2011000628A patent/PE20110793A1/es not_active Application Discontinuation
- 2009-09-16 EA EA201100368A patent/EA201100368A1/ru unknown
- 2009-09-16 CN CN2009801364939A patent/CN102159548A/zh active Pending
- 2009-09-16 BR BRPI0918935A patent/BRPI0918935A2/pt not_active IP Right Cessation
- 2009-09-16 MX MX2011002899A patent/MX2011002899A/es not_active Application Discontinuation
- 2009-09-17 US US12/561,398 patent/US8232269B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 IL IL211479A patent/IL211479A0/en unknown
- 2011-03-17 DO DO2011000083A patent/DOP2011000083A/es unknown
- 2011-03-17 EC EC2011010901A patent/ECSP11010901A/es unknown
- 2011-03-17 CL CL2011000570A patent/CL2011000570A1/es unknown
- 2011-03-18 MA MA33710A patent/MA32642B1/fr unknown
- 2011-03-25 CO CO11036952A patent/CO6351734A2/es not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02690A patent/ZA201102690B/en unknown
-
2012
- 2012-06-18 US US13/525,893 patent/US20120316150A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009294290B2 (en) | 2012-08-30 |
| US20100249091A1 (en) | 2010-09-30 |
| US8232269B2 (en) | 2012-07-31 |
| AU2009294290A1 (en) | 2010-03-25 |
| EP2350017A1 (en) | 2011-08-03 |
| WO2010032200A1 (en) | 2010-03-25 |
| IL211479A0 (en) | 2011-05-31 |
| US20120316150A1 (en) | 2012-12-13 |
| MA32642B1 (fr) | 2011-09-01 |
| BRPI0918935A2 (pt) | 2015-12-01 |
| ECSP11010901A (es) | 2011-04-29 |
| CA2735931A1 (en) | 2010-03-25 |
| MX2011002899A (es) | 2011-04-11 |
| EA201100368A1 (ru) | 2011-12-30 |
| DOP2011000083A (es) | 2011-03-31 |
| CN102159548A (zh) | 2011-08-17 |
| ZA201102690B (en) | 2011-12-28 |
| CO6351734A2 (es) | 2011-12-20 |
| AP2011005611A0 (en) | 2011-04-30 |
| JP2012502975A (ja) | 2012-02-02 |
| KR20110044304A (ko) | 2011-04-28 |
| CL2011000570A1 (es) | 2011-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110793A1 (es) | Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona | |
| PE20081659A1 (es) | Agonistas de gpcr | |
| PE20142099A1 (es) | Derivados de sulfonamida | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20081884A1 (es) | Inhibidores heterociclicos de la aspartil proteasa | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
| PE20090893A1 (es) | Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5 | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| PE20141529A1 (es) | Derivados de biciclo [3,2,1] octilamida y sus usos | |
| PE20081849A1 (es) | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr | |
| PE20120403A1 (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
| PE20121522A1 (es) | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae | |
| PE20130647A1 (es) | Indoles | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20141375A1 (es) | Activadores de glucoquinasa | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| PE20121010A1 (es) | Derivados de bencimidazol | |
| PE20110303A1 (es) | Derivados de heteroaril acetamidas como activadores de glucoquinasa | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| PE20080150A1 (es) | Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |